Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy

被引：38
作者：
Rizzo, Alessandro [1 ]
Ricci, Angela Dalia [2 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med La Pr, Viale Orazio Flacco 65, I-70124 Bari, Italy
[2] Saverio de Bellis Res Hosp, Natl Inst Gastroenterol, Med Oncol Unit, I-70013 Castellana Grotte, Italy
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 19期
关键词：
BEVACIZUMAB; PLUS;
D O I：
10.3390/ijms231911363
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 28 条
[1]   Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [J].
Abou-Alfa, Ghassan K. ;
Chan, Stephen Lam ;
Kudo, Masatoshi ;
Lau, George ;
Kelley, Robin Kate ;
Furuse, Junji ;
Sukeepaisarnjaroen, Wattana ;
Kang, Yoon-Koo ;
Dao, Tu V. ;
De Toni, Enrico N. ;
Rimassa, Lorenza ;
Breder, Valeriy Vladimirovich ;
Vasilyev, Alexander ;
Heurgue, Alexandra ;
Tam, Vincent ;
Mody, Kabir ;
Thungappa, Satheesh Chiradoni ;
He, Philip ;
Negro, Alejandra ;
Sangro, Bruno .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[2]   Hepatobiliary Cancers, Version 2.2021 [J].
Benson III, Al B. ;
D'Angelica, Michael I. ;
Abbott, Daniel E. ;
Anaya, Daniel A. ;
Anders, Robert ;
Are, Chandrakanth ;
Bachini, Melinda ;
Borad, Mitesh ;
Brown, Daniel ;
Burgoyne, Adam ;
Chahal, Prabhleen ;
Chang, Daniel T. ;
Cloyd, Jordan ;
Covey, Anne M. ;
Glazer, Evan S. ;
Goyal, Lipika ;
Hawkins, William G. ;
Iyer, Renuka ;
Jacob, Rojymon ;
Kelley, R. Kate ;
Kim, Robin ;
Levine, Matthew ;
Palta, Manisha ;
Park, James O. ;
Raman, Steven ;
Reddy, Sanjay ;
Sahai, Vaibhav ;
Schefter, Tracey ;
Singh, Gagandeep ;
Stein, Stacey ;
Vauthey, Jean-Nicolas ;
Venook, Alan P. ;
Yopp, Adam ;
McMillian, Nicole R. ;
Hochstetler, Cindy ;
Darlow, Susan D. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (05) :541-565
[3]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[4]   Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond [J].
Feng, Maple Ye ;
Chan, Landon L. ;
Chan, Stephen Lam .
CURRENT ONCOLOGY, 2022, 29 (08) :5489-5507
[5]   IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). [J].
Finn, Richard S. ;
Qin Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Lim, Ho Yeong ;
Kudo, Masatoshi ;
Breder, Valeriy Vladimirovich ;
Merle, Philippe ;
Kaseb, Ahmed Omar ;
Li Daneng ;
Verret, Wendy ;
Shao Hui ;
Liu Juan ;
Li Lindong ;
Zhu, Andrew X. ;
Chen, Ann-Lii .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[6]   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Qin, Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Kudo, Masatoshi ;
Breder, Valeriy ;
Merle, Philippe ;
Kaseb, Ahmed O. ;
Li, Daneng ;
Verret, Wendy ;
Xu, Derek-Zhen ;
Hernandez, Sairy ;
Liu, Juan ;
Huang, Chen ;
Mulla, Sohail ;
Wang, Yulei ;
Lim, Ho Yeong ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905
[7]   Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J].
Finn, Richard S. ;
Ryoo, Baek-Yeol ;
Merle, Philippe ;
Kudo, Masatoshi ;
Bouattour, Mohamed ;
Lim, Ho Yeong ;
Breder, Valeriy ;
Edeline, Julien ;
Chao, Yee ;
Ogasawara, Sadahisa ;
Yau, Thomas ;
Garrido, Marcelo ;
Chan, Stephen L. ;
Knox, Jennifer ;
Daniele, Bruno ;
Ebbinghaus, Scot W. ;
Chen, Erluo ;
Siegel, Abby B. ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) :193-+
[8]   Emerging immunotherapy or HCC: A guide for hepatologists [J].
Foerster, Friedrich ;
Gairing, Simon Johannes ;
Ilyas, Sumera Irie ;
Galle, Peter Robert .
HEPATOLOGY, 2022, 75 (06) :1604-1626
[9]   Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial [J].
Kelley, Robin Kate ;
Rimassa, Lorenza ;
Cheng, Ann-Lii ;
Kaseb, Ahmed ;
Qin, Shukui ;
Zhu, Andrew X. ;
Chan, Stephen L. ;
Melkadze, Tamar ;
Sukeepaisarnjaroen, Wattana ;
Breder, Valery ;
Verset, Gontran ;
Gane, Edward ;
Borbath, Ivan ;
Rangel, Jose David Gomez ;
Ryoo, Baek-Yeol ;
Makharadze, Tamta ;
Merle, Philippe ;
Benzaghou, Fawzi ;
Banerjee, Kamalika ;
Hazra, Saswati ;
Fawcett, Jonathan ;
Yau, Thomas .
LANCET ONCOLOGY, 2022, 23 (08) :995-1008
[10]   Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects [J].
Liu, Zhuoyan ;
Liu, Xuan ;
Liang, Jiaxin ;
Liu, Yixin ;
Hou, Xiaorui ;
Zhang, Meichuan ;
Li, Yongyin ;
Jiang, Xiaotao .
FRONTIERS IN IMMUNOLOGY, 2021, 12
123